Orchid Pharma faced a tough Q2 & H1 FY26. **Business Performance:** Sales for Q2 FY26 dropped 13% YoY to 194 Cr, and H1 FY26 revenue decreased 22% to 366 Cr.

Profitability took a significant hit, with Q2 PAT plummeting 92% YoY to 2 Cr, and H1 PAT down 64% to 20 Cr.

A major factor was the Gross Margin, which shrank to 32% in Q2 FY26 from 41% in Q2 FY25. This also pulled down EBITDA margins from 17% to 8% YoY. **Growth Drivers or Strategy:** This presentation did not outline specific growth drivers or strategic focus areas. **Recent Developments:** No notable product launches, capacity expansions, or customer wins were disclosed. **Management Commentary / Outlook:** No management commentary or future outlook was provided in this presentation.